MGMT promoter methylation

Noninvasive imaging parameters extracted from QSM images can reflect glioma WHO grade, molecular markers, prognosis, and recurrence risk. These preliminary findings showed that the QSM might be a noninvasive imaging biomarker for comprehensive evaluation of adult-type diffuse gliomas.

P1, N=27, Recruiting, Washington University School of Medicine | N=12 --> 27

Both pre- and postoperative models successfully predict short-term recurrence in elderly glioma patients. Key clinical risk factors, such as tumors infiltrating the corpus callosum and various tumor-related symptoms were identified. Additionally, certain common postoperative physical and psychological symptom changes in the MDASI-BT may be predictive markers for long-term relapse. A crucial finding is that the factors associated with recurrence are distinct across molecular subtypes, underscoring the need for subtype-specific risk management.

The identified qMSP cut-off value (0.242) based on the procedure described in this study provides a robust prognostic stratification tool for GBM patients. High MGMT methylation correlates with improved survival, supporting its integration into clinical decision-making. Further multi-center validation studies are warranted to establish standardized MGMT assessment methodologies.

Future directions include a larger GBM Study allowing multivariable analysis, and other solid, potentially curable, cancer studies, where we envisage providing a Mn threshold to aid clinicians' decision making.

The accurate prediction of MGMT promoter methylation status via non-invasive imaging provides a reliable criterion for anticipating patient responsiveness to alkylating chemotherapy. This capability equips clinicians with a tool to inform personalized treatment strategies, optimizing therapeutic efficacy from the outset.

Our federated multi-task deep learning model demonstrates the feasibility and effectiveness of predicting glioma molecular characteristics and grade from multi-parametric MRI, without compromising patient privacy. These findings suggest significant potential for clinical deployment, especially in scenarios where invasive tissue sampling is impractical or risky.

We assessed drug use at baseline and defined 3 landmarks: start of temozolomide maintenance cycles 1 (landmark 1) and 4 (landmark 2), and end of cycle 6 (landmark 3)...Translational research studies should explore whether PPI-induced activity of ALDH mediates the potential adverse effects of PPI in glioblastoma. .

P2/3, N=144, Active, not recruiting, Laminar Pharmaceuticals | Trial completion date: May 2025 --> Nov 2026 | Trial primary completion date: Oct 2024 --> Jan 2026

P=N/A, N=18, Suspended, Royal Adelaide Hospital | Recruiting --> Suspended

The GLIMMER score suggests potential ultra-rapid, non-invasive intraoperative estimation of MGMT promoter methylation with high diagnostic performance. These findings necessitate further validation with in-vivo HSI-guided biopsies to guide future personalized resection strategies in glioma patients.

We propose a "spatial-epigenetic precision pipeline" involving: (1) mapping niche-specific epigenetic signatures via spatial multi-omics; (2) developing ligand-functionalized nanocarriers for targeted delivery; and (3) designing adaptive combinatory regimens (epigenetic agents with radiotherapy and immunotherapy) based on dynamic response monitoring. This framework aims to disrupt spatial-epigenetic crosstalk, potentially transforming GBM into a chronically manageable disease.